High-dose epirubicin in chemotherapy refractory non-seminomatous germ cell cancer: a phase II study. EORTC Genito-Urinary Tract Cancer Co-operative Group. EORTC Early Clinical Trials Group. 1992

G Stoter, and A Akdas, and S D Fosså, and S B Kaye, and C J van Groeningen, and J Renard, and M van Glabbeke
Department of Medical Oncology, Rotterdam Cancer Institute, The Netherlands.

Eighteen patients with progressive disseminated, platinum-resistant germ cell tumors were treated with epirubicin 135 mg/m2, every 3 weeks. One patient had stable disease, 17 developed progression. Myelosuppression was dose-limiting. One patient died of neutropenic septicemia. High-dose epirubicin is not active against platinum-resistant germ cell cancer.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009373 Neoplasms, Germ Cell and Embryonal Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS. Germ Cell Cancer,Germ Cell Tumor,Neoplasms, Embryonal and Mixed,Cancer, Embryonal,Cancer, Embryonal and Mixed,Embryonal Neoplasms,Germ Cell Neoplasms,Germ Cell and Embryonal Neoplasms,Germ Cell and Embryonic Neoplasms,Neoplasms, Embryonal,Neoplasms, Germ Cell,Neoplasms, Germ Cell and Embryonic,Cancer, Germ Cell,Cancers, Embryonal,Cancers, Germ Cell,Embryonal Cancer,Embryonal Cancers,Embryonal Neoplasm,Germ Cell Cancers,Germ Cell Tumors,Neoplasm, Embryonal,Tumor, Germ Cell,Tumors, Germ Cell
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015251 Epirubicin An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. 4'-Epiadriamycin,4'-Epidoxorubicin,4'-Epi-Adriamycin,4'-Epi-DXR,4'-Epi-Doxorubicin,EPI-cell,Ellence,Epilem,Epirubicin Hydrochloride,Farmorubicin,Farmorubicina,Farmorubicine,IMI-28,NSC-256942,Pharmorubicin,4' Epi Adriamycin,4' Epi DXR,4' Epi Doxorubicin,4' Epiadriamycin,4' Epidoxorubicin,EPI cell,EPIcell,Hydrochloride, Epirubicin,IMI 28,IMI28,NSC 256942,NSC256942

Related Publications

G Stoter, and A Akdas, and S D Fosså, and S B Kaye, and C J van Groeningen, and J Renard, and M van Glabbeke
September 1990, Annals of oncology : official journal of the European Society for Medical Oncology,
G Stoter, and A Akdas, and S D Fosså, and S B Kaye, and C J van Groeningen, and J Renard, and M van Glabbeke
May 1992, Annals of oncology : official journal of the European Society for Medical Oncology,
G Stoter, and A Akdas, and S D Fosså, and S B Kaye, and C J van Groeningen, and J Renard, and M van Glabbeke
January 1985, Investigational new drugs,
G Stoter, and A Akdas, and S D Fosså, and S B Kaye, and C J van Groeningen, and J Renard, and M van Glabbeke
February 1992, Seminars in urology,
G Stoter, and A Akdas, and S D Fosså, and S B Kaye, and C J van Groeningen, and J Renard, and M van Glabbeke
September 1985, European journal of cancer & clinical oncology,
G Stoter, and A Akdas, and S D Fosså, and S B Kaye, and C J van Groeningen, and J Renard, and M van Glabbeke
January 1988, Progress in clinical and biological research,
G Stoter, and A Akdas, and S D Fosså, and S B Kaye, and C J van Groeningen, and J Renard, and M van Glabbeke
June 1984, European journal of cancer & clinical oncology,
G Stoter, and A Akdas, and S D Fosså, and S B Kaye, and C J van Groeningen, and J Renard, and M van Glabbeke
December 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G Stoter, and A Akdas, and S D Fosså, and S B Kaye, and C J van Groeningen, and J Renard, and M van Glabbeke
October 1995, Annals of oncology : official journal of the European Society for Medical Oncology,
G Stoter, and A Akdas, and S D Fosså, and S B Kaye, and C J van Groeningen, and J Renard, and M van Glabbeke
October 1984, European journal of cancer & clinical oncology,
Copied contents to your clipboard!